Active Ingredient(s):Nilotinib Hydrochloride Monohydrate FDA Approved: * October 29, 2007 Pharm Company: *NOVARTIS Category:Cancer
Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. It is taken by mouth.
Common side effects may include low platelets, low white blood cells, anemia...
* May have multiple approval dates, manufacturers, or labelers. 4 Discussions